| Section of Cytopathology The Section of Cytopathology 
                    provides a diverse cytopathology service and also runs a large 
                    training program.
 The Cytopathology Service comprises three 
                      main areas: 
                     
                      Exfoliative Cytopathology 
                      Fine Needle Aspiration Service 
                      Image Analysis 
                     Exfoliative CytopathologyExfoliative Cytopathology encompasses gynecologic specimens, 
                      including Pap Smears, Non-Gynecological specimens and Outside 
                      slides. Specimens are received from various clinics and 
                      inpatient floors in the main processing lab. Specimens are 
                      concentrated, stained, cover slipped, slides for special 
                      studies and cellblocks prepared and the specimens sent to 
                      the cytotechnologists for preliminary screening. In contrast 
                      to most hospitals and because of the high prevalence of 
                      pre-neoplastic lesions, most of our gynecological cytopathology 
                      specimens are required to be evaluated by a cytopathologist.
 Fine Needle Aspiration 
                      ServiceWith the advent of managed care, the demand for low-cost, 
                      high-turnaround types of diagnostic procedures has increased, 
                      and FNA biopsies fulfill these requirements. This service 
                      comprises both superficial aspiration and deep aspiration 
                      components. At MDACC, many FNA biopsies are performed by 
                      cytopathologists. The aspirated material is immediately 
                      smeared, stained and evaluated, and a preliminary diagnosis 
                      is issued while the patient is still waiting in the clinic. 
                      The deep aspirations are procured by radiologists under 
                      guidance (including fluoroscopy, CT scan and ultrasound) 
                      and require immediate cytological assessment of adequacy, 
                      specimen triage and subsequent interpretation. In cases 
                      of unclassified neoplasms, lymphoproliferative disorders 
                      and breast cancer, additional passes are obtained for immunocytochemistry 
                      markers, flow cytometry, cytogenetic and molecular studies 
                      as indicated. In many instances, the FNA diagnosis is reinforced 
                      by ancillary tests on the aspirated cells, and the clinical 
                      findings are the working diagnosis on which definitive therapy 
                      is based.
 Because of the diversity and primary diagnostic 
                      nature of many of the aspiration specimens, heavy emphasis 
                      is placed on the use of ancillary studies for both diagnosis 
                      and prognosis (ie. lymphoma surface markers, ER/PR, proliferation 
                      index by Ki67 and DNA ploidy. A final cytopathology report 
                      integrates all the ancillary studies. 
                     Through the FNA service, a cytopathology 
                      tumor bank has been established. All remaining aspirated 
                      tissues/cells are stored for future research studies. The 
                      bank comprises over 5,000 lymphomas, breast carcinomas and 
                      melanoma aspirates. The total number of stored cases is 
                      about 11,000 specimens. Some of the archived material has 
                      been used in the development of several research projects. 
                      
                     Image Analysis 
                      The image analysis laboratory provides an interactive DNA 
                      quantitation service for ploidy, proliferation and antigen 
                      quantitation (estrogen and progesterone receptors and Ki-67).
 |